Healthcare / Medical DevicesSão Paulo
$8.70
-0.30 (-3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-75.7M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-40.0%
↓Gross Margin
74.5%
↑Debt/Equity
0.73
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
—
FCF margin
-11.5%
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $655.4M · net income $-136.2M · FCF $-75.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $655.4M | $655.4M | $605.2M | $509.3M | $537.8M |
| Net Income | $-136.2M | $-136.2M | $-168.6M | $-207.0M | $-92.5M |
| EBITDA | $-104.6M | $-104.6M | $-109.6M | $-177.5M | $-67.9M |
| EPS | -1.22 | -1.22 | -1.56 | -1.95 | -0.88 |
| Gross Margin | 74.5% | 74.5% | 77.3% | 74.8% | 78.6% |
| Operating Margin | -23.5% | -23.5% | -28.2% | -45.7% | -16.6% |
| Net Margin | -20.8% | -20.8% | -27.9% | -40.6% | -17.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.73 | 0.73 | 1.90 | 1.67 | 1.32 |
| Current Ratio | 2.90 | 2.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-75.7M | $-75.7M | $-69.2M | $-100.4M | $9.4M |
| Returns | |||||
| ROE | -40.0% | -40.0% | -46.8% | -57.1% | -21.0% |
| Valuation | |||||
| P/B | 2.85 | 2.85 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 8.3% | 8.3% | 18.8% | -5.3% | — |
| EPS Growth | 21.8% | 21.8% | 20.0% | -121.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+62.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.56 → -1.22
Residual
+62.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.